Le Lézard
Classified in: Health, Science and technology, Business
Subjects: FNC, ACC, VEN, TRI

Strekin AG Secures Financing to Complete Development of STR001 in Sudden Sensorineural Hearing Loss and to Prepare NDA Filing in Europe


BASEL, Switzerland, Sept. 3, 2019 /CNW/ -- Strekin AG (www.strekin.com), a clinical stage biopharmaceutical company, announced today that it has successfully closed a Series A financing round totaling CHF 2.82 Million from private investors. These funds will enable Strekin to conclude its ongoing Phase 3 clinical trial of STR001 in Sudden Sensorineural Hearing Loss, the RESTORE trial, and to prepare for a European filing.

Strekin Logo (PRNewsfoto/Strekin)

STR001 is Strekin's lead drug candidate. Preclinical data published by Strekin and its collaborators demonstrated that STR001 effectively protects hearing in animal models by blocking oxidative stress and reducing activation of inflammatory signaling in the cochlea. The RESTORE trial is an international, randomized, placebo-controlled Phase 3 clinical trial of STR001 in patients suffering from a sudden sensorineural hearing loss event. STR001 has been very well tolerated and topline results from RESTORE are anticipated to be released in early 2020.

"With the funding from Series A we have now the financial flexibility to finish the ongoing clinical study, to prepare an NDA filing in Europe, and to drive a corporate exit either via IPO or trade sale," remarked Alexander Bausch, Strekin's Chief Executive Office and founder. "The RESTORE trial tests the ability of STR001 to address a clear unmet medical need in patients who have suffered an event that may lead to severe life-long hearing loss. If successful, the data provided by RESTORE, along with the orphan drug status of STR001 for SSNHL, may allow Strekin to quickly launch STR001 in Europe."  

About Sudden Sensorineural Hearing Loss

Sudden sensorineural hearing loss (SSNHL) is an acute loss of hearing caused by damage to the sound-sensing hair cells of the inner ear. SSHNL may be caused by surgery, acoustic trauma, or sudden deafness, a phenomenon in which hearing loss occurs without obvious cause. Further symptoms may include ringing in the ears (tinnitus) and dizziness (vertigo). Sudden hearing loss is a medical emergency. Individuals who perceive a sudden change in their hearing are recommended to contact their health care provider without delay. Hearing loss makes daily activities most people take for granted, like having a conversation, enjoying music, and communicating effectively in the work environment, difficult or impossible. There are currently no approved drugs available for the treatment of SSNHL.

About Strekin

Strekin AG (www.strekin.com) is a Swiss-based biopharmaceutical company advancing therapeutics for improved patient benefit in diseases with high unmet need. Strekin is led by a team of experts with extensive experience in successful discovery, development, and commercialization of new drugs. Strekin is privately funded by a broad base of investors.

Logo - https://mma.prnewswire.com/media/967922/strekin_Logo.jpg

Alexander Bausch,
CEO, Strekin AG
E-Mail: Alexander.Bausch@strekin.com

 

SOURCE Strekin


These press releases may also interest you

at 00:10
Verseau Therapeutics, Inc. ("Verseau") launched today with $50 million in financing from 20/20 HealthCare Partners, 3SBio, Alexandria Venture Investments, Highlight Capital, InHarv Partners Ltd., The Mark Foundation for Cancer Research and Yonghua...

at 00:00
How to Address Medical Device Sample Size Issues What Regulatory and Quality Professionals Absolutely Must Know **An FDAnews Webinar** Tuesday, Nov. 5, 2019, 1:30-3:00 p.m. EST https://www.fdanews.com/addressmedicaldevice What impact do statistical...

at 00:00
PlaySight Interactive is excited today to officially announce the launch and release of the SmartCourt GO ? a fully portable and mobile version of PlaySight's Smart AI and connected camera sports video technology platform, powered by LiveU IP video...

20 oct 2019
The Year in Infrastructure Conference -- Digital Construction Works, Inc. (DCW), a new digital automation, integration, and digital twinning services company announces the launch of its Partner Community, including partners to provide services and...

20 oct 2019
The Year in Infrastructure 2019 Conference -- Bentley Systems, Incorporated, the leading global provider of comprehensive software and digital twin cloud services for advancing the design, construction, and operations of infrastructure, today...

20 oct 2019
The Year in Infrastructure Conference -- Digital Construction Works (DCW), a new digital automation, integration, and digital twinning services and fit-for-purpose solutions company formed by Bentley Systems and Topcon Positioning Group, will help...



News published on 3 september 2019 at 02:00 and distributed by: